Xconomy | Boston - Business + Technology in the Exponential Economy

Forma, Novartis Strike Drug Deal
Broad Institute Scientists’ Forma Therapeutics Raises $25M, Aims to Knock Out Underpinnings of Cancer
Forma Forms Antibiotic-Discovery Partnership with Cubist
Novartis Option Fund Managing Director Says First Responsibility is to Portfolio Companies, Dislikes “Corporate VC” Moniker
Cubist and Alnylam Tackle RSV, Exact Sciences Fends Off Sequenom, An FDA Panel Backs GTC Biotherapeutics’ Goat-Milk Drug, & More Boston-Area Life Sciences News

Forma and Novartis Form Cancer Drug Collaboration

Forma Therapeutics, a Cambridge, MA-based biotech firm, said this morning that it has landed a drug-discovery collaboration with Swiss drug giant Novartis. Novartis, which has previously invested in Forma through its Novartis Option Fund, is tapping the biotech startup to apply its cell-based screening platform to discover inhibitor treatments that target protein-to-protein interactions in cancer. Financial terms of the deal and specific drug targets involved weren’t disclosed.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share: